Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman, MD | #ASH24

Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman, MD | #ASH24

Ethnic Disparities in Myeloma Outcomes | Muzaffar Qazilbash, MD | #ASH24

Ethnic Disparities in Myeloma Outcomes | Muzaffar Qazilbash, MD | #ASH24

Comparing Outcomes in Younger Multiple Myeloma Patients | Marc Braunstein, MD, PhD | #ASH24

Comparing Outcomes in Younger Multiple Myeloma Patients | Marc Braunstein, MD, PhD | #ASH24

Demonstrating Better Protection with 3 Flu Shots in Myeloma | Craig Hofmeister, MD, MPH | #ASH24

Demonstrating Better Protection with 3 Flu Shots in Myeloma | Craig Hofmeister, MD, MPH | #ASH24

High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma | Urvi Shah, MD | #ASH24

High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma | Urvi Shah, MD | #ASH24

Does enhanced genetic testing impact myeloma patients? | Santiago Thibaud, MD | #ASH24

Does enhanced genetic testing impact myeloma patients? | Santiago Thibaud, MD | #ASH24

Loss of CD38 and Resistance Patterns in Myeloma | Benjamin Diamond, MD | #ASH24

Loss of CD38 and Resistance Patterns in Myeloma | Benjamin Diamond, MD | #ASH24

Impact of High-Risk Cytogenetics in Primary Plasma Cell Leukemia | Wilson Gonsalves, MD | #ASH24

IVIG and Preventing Infections in Myeloma Patients on Teclistamab | Heloise Cheruvalath | #ASH24

IVIG and Preventing Infections in Myeloma Patients on Teclistamab | Heloise Cheruvalath | #ASH24

Early Identification of Toxicity & Responses to BCMA CAR-T Therapy in RRMM | Kai Rejeski, MD |#ASH24

CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24

CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24

Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma